Northern Trust: Vanda Pharmaceuticals VNDA Historial de posiciones en acciones
Comprado
Mantenidas
Vendido
| Trimestre | Valor de mercado | Estado | Acciones |
Cambio en la posición | Valor operado | Peso en el portafolio | Puesto en el portafolio | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | USD 2.83 M | Venta |
577,091
-23,528
| -4% | -USD 126 k | ﹤0.01% | 2862 |
|
|
2026
Q2 | USD 3.68 M | Compra |
600,619
+149,638
| +33% | +USD 977 k | ﹤0.01% | 2790 |
|
|
2026
Q1 | USD 3.12 M | Compra |
450,981
+21,868
| +5% | +USD 169 k | ﹤0.01% | 2722 |
|
|
2025
Q4 | USD 3.78 M | Venta |
429,113
-25,459
| -6% | -USD 140 k | ﹤0.01% | 2632 |
|
|
2025
Q3 | USD 2.27 M | Venta |
454,572
-4,552
| -1% | -USD 21.1 k | ﹤0.01% | 2962 |
|
|
2025
Q2 | USD 2.17 M | Venta |
459,124
-30,250
| -6% | -USD 132 k | ﹤0.01% | 2938 |
|
|
2025
Q1 | USD 2.25 M | Venta |
489,374
-18,068
| -4% | -USD 84.2 k | ﹤0.01% | 2858 |
|
|
2024
Q4 | USD 2.43 M | Compra |
507,442
+6,283
| +1% | +USD 30.2 k | ﹤0.01% | 2912 |
|
|
2024
Q3 | USD 2.35 M | Compra |
501,159
+14,248
| +3% | +USD 76.4 k | ﹤0.01% | 2900 |
|
|
2024
Q2 | USD 2.75 M | Venta |
486,911
-7,829
| -2% | -USD 40.4 k | ﹤0.01% | 2730 |
|
|
2024
Q1 | USD 2.03 M | Venta |
494,740
-13,845
| -3% | -USD 55.4 k | ﹤0.01% | 2951 |
|
|
2023
Q4 | USD 2.15 M | Venta |
508,585
-52,752
| -9% | -USD 213 k | ﹤0.01% | 2970 |
|
|
2023
Q3 | USD 2.42 M | Venta |
561,337
-34,163
| -6% | -USD 190 k | ﹤0.01% | 2830 |
|
|
2023
Q2 | USD 3.92 M | Venta |
595,500
-783
| -0.1% | -USD 5.02 k | ﹤0.01% | 2637 |
|
|
2023
Q1 | USD 4.05 M | Compra |
596,283
+10,260
| +2% | +USD 72.1 k | ﹤0.01% | 2586 |
|
|
2022
Q4 | USD 4.33 M | Venta |
586,023
-8,567
| -1% | -USD 83.4 k | ﹤0.01% | 2570 |
|
|
2022
Q3 | USD 5.88 M | Venta |
594,590
-2,551
| -0.4% | -USD 26.9 k | ﹤0.01% | 2371 |
|
|
2022
Q2 | USD 6.51 M | Compra |
597,141
+232
| +0% | +USD 2.4 k | ﹤0.01% | 2335 |
|
|
2022
Q1 | USD 6.75 M | Venta |
596,909
-195,342
| -25% | -USD 2.57 M | ﹤0.01% | 2396 |
|
|
2021
Q4 | USD 12.4 M | Venta |
792,251
-7,221
| -0.9% | -USD 126 k | ﹤0.01% | 2083 |
|
|
2021
Q3 | USD 13.7 M | Venta |
799,472
-20,681
| -3% | -USD 362 k | ﹤0.01% | 2055 |
|
|
2021
Q2 | USD 17.6 M | Compra |
820,153
+194,483
| +31% | +USD 3.48 M | ﹤0.01% | 1974 |
|
|
2021
Q1 | USD 9.4 M | Venta |
625,670
-24,562
| -4% | -USD 398 k | ﹤0.01% | 2336 |
|
|
2020
Q4 | USD 8.54 M | Venta |
650,232
-33,695
| -5% | -USD 406 k | ﹤0.01% | 2352 |
|
|
2020
Q3 | USD 6.61 M | Venta |
683,927
-27,624
| -4% | -USD 295 k | ﹤0.01% | 2366 |
|
|
2020
Q2 | USD 8.14 M | Venta |
711,551
-8,525
| -1% | -USD 96.5 k | ﹤0.01% | 2226 |
|
|
2020
Q1 | USD 7.46 M | Compra |
720,076
+4,126
| +0.6% | +USD 51.2 k | ﹤0.01% | 2068 |
|
|
2019
Q4 | USD 11.7 M | Venta |
715,950
-16,983
| -2% | -USD 257 k | ﹤0.01% | 2078 |
|
|
2019
Q3 | USD 9.7 M | Compra |
732,933
+26,267
| +4% | +USD 366 k | ﹤0.01% | 2161 |
|
|
2019
Q2 | USD 10 M | Compra |
706,666
+6,938
| +1% | +USD 110 k | ﹤0.01% | 2161 |
|
|
2019
Q1 | USD 12.9 M | Compra |
699,728
+4,290
| +0.6% | +USD 97.8 k | ﹤0.01% | 1984 |
|
|
2018
Q4 | USD 18.2 M | Venta |
695,438
-6,583
| -0.9% | -USD 155 k | 0.01% | 1664 |
|
|
2018
Q3 | USD 16.1 M | Compra |
702,021
+25,721
| +4% | +USD 525 k | ﹤0.01% | 1945 |
|
|
2018
Q2 | USD 12.9 M | Compra |
676,300
+91,539
| +16% | +USD 1.53 M | ﹤0.01% | 2097 |
|
|
2018
Q1 | USD 9.9 M | Compra |
584,761
+6,730
| +1% | +USD 113 k | ﹤0.01% | 2179 |
|
|
2017
Q4 | USD 8.79 M | Venta |
578,031
-13,755
| -2% | -USD 204 k | ﹤0.01% | 2274 |
|
|
2017
Q3 | USD 10.6 M | Venta |
591,786
-6,142
| -1% | -USD 103 k | ﹤0.01% | 2166 |
|
|
2017
Q2 | USD 9.7 M | Compra |
597,928
+84,834
| +17% | +USD 1.22 M | ﹤0.01% | 2197 |
|
|
2017
Q1 | USD 7.18 M | Compra |
513,094
+28,542
| +6% | +USD 407 k | ﹤0.01% | 2339 |
|
|
2016
Q4 | USD 7.73 M | Compra |
484,552
+2,533
| +0.5% | +USD 40.7 k | ﹤0.01% | 2272 |
|
|
2016
Q3 | USD 8.02 M | Venta |
482,019
-578
| -0.1% | -USD 7.78 k | ﹤0.01% | 2210 |
|
|
2016
Q2 | USD 5.4 M | Venta |
482,597
-46,656
| -9% | -USD 452 k | ﹤0.01% | 2401 |
|
|
2016
Q1 | USD 4.42 M | Compra |
529,253
+23,202
| +5% | +USD 190 k | ﹤0.01% | 2481 |
|
|
2015
Q4 | USD 4.71 M | Compra |
506,051
+28,620
| +6% | +USD 286 k | ﹤0.01% | 2490 |
|
|
2015
Q3 | USD 5.38 M | Compra |
477,431
+63,275
| +15% | +USD 774 k | ﹤0.01% | 2396 |
|
|
2015
Q2 | USD 5.26 M | Venta |
414,156
-48,446
| -10% | -USD 522 k | ﹤0.01% | 2481 |
|
|
2015
Q1 | USD 4.3 M | Compra |
462,602
+14,804
| +3% | +USD 167 k | ﹤0.01% | 2600 |
|
|
2014
Q4 | USD 6.41 M | Compra |
447,798
+43,874
| +11% | +USD 519 k | ﹤0.01% | 2339 |
|
|
2014
Q3 | USD 4.19 M | Compra |
403,924
+3,060
| +0.8% | +USD 40.1 k | ﹤0.01% | 2622 |
|
|
2014
Q2 | USD 6.49 M | Venta |
400,864
-47,223
| -11% | -USD 629 k | ﹤0.01% | 2347 |
|
|
2014
Q1 | USD 7.28 M | Venta |
448,087
-44,319
| -9% | -USD 630 k | ﹤0.01% | 2322 |
|
|
2013
Q4 | USD 6.11 M | Compra |
492,406
+45,012
| +10% | +USD 452 k | ﹤0.01% | 2417 |
|
|
2013
Q3 | USD 4.9 M | Compra |
447,394
+48,214
| +12% | +USD 515 k | ﹤0.01% | 2520 |
|
|
2013
Q2 | USD 3.23 M | Compra |
+399,180
| Nuevas | +USD 2.69 M | ﹤0.01% | 2687 |
|
Otros fondos que tienen VNDA en su portafolio
ACM
Posición de Northern Trust en VNDA: resumen de T3 2026
Northern Trust redujo su participación en Vanda Pharmaceuticals (VNDA) en 3.9% durante T3 2026, al vender acciones por un valor estimado de USD 126 k y quedarse con 577,091 acciones valuadas en USD 2.83 M. La posición representa ﹤0.01% del portafolio y ocupa el puesto #2862.
Northern Trust reportó por primera vez una posición en VNDA en T2 2013 y desde entonces la ha mantenido en 54 trimestres. La posición alcanzó su máximo de USD 18.2 M en T4 2018. Al cierre de T3 2026, 152 fondos que sigue Wall St. Rank mantienen una posición en VNDA.
- Al cierre de T3 2026, Northern Trust tenía 577,091 acciones de Vanda Pharmaceuticals con un valor de USD 2.83 M.
- Northern Trust vendió 23,528 acciones de Vanda Pharmaceuticals en T3 2026, por un valor estimado de USD 126 k.
- Vanda Pharmaceuticals representó el ﹤0.01% del portafolio de Northern Trust en T3 2026 y fue su posición número 2862.
- Northern Trust reportó por primera vez una posición en Vanda Pharmaceuticals en T2 2013 y desde entonces la ha mantenido en 54 trimestres.
- La posición de Northern Trust en Vanda Pharmaceuticals alcanzó su máximo de USD 18.2 M en T4 2018.
- Al cierre de T3 2026, 152 fondos que sigue Wall St. Rank tenían Vanda Pharmaceuticals en su portafolio.
Según el informe 13F de Northern Trust correspondiente a T3 2026, presentado el 16 nov 2026.